Asarina Pharma

Asarina Pharma (previously Umecrine Mood) is developing novel and targeted products to treat women with severe symptoms associated with the menstrual cycle such as premenstrual dysphoric disorder (PMDD), allowing these women to remain in control of their own life.

There are currently no products specifically developed to treat PMDD. Patients are most often prescribed anti-depressants (SSRI’s) or oral contraceptives (OC) for symptom relief. These treatments only gives symptom relief in some PMDD patients and are often associated with unacceptable side effects, including e.g. increased risk of thrombosis with some OCs. Asarina Pharma intends to develop Sepranolone as a unique first-in-class opportunity to address the need for improved treatments for PMDD.